Long-term culture of patient-derived mammary organoids in non-biogenic electrospun scaffolds for identifying metalloprotein and motor protein activities in aging and senescence.

3D cell culture Aging Animal component free tissue cultures Autophagosomes Autophagy Breast Electrospinning Golgi complex Hallmarks in aging Lysosomes Metalloproteins Mitochondria Motor proteins Organoids Polydimethylsiloxane Proteosomes RNASET2 Senescence Senescent associated secreted phenotype (SASP) Skin Stem cells (SC) TMEM230

Journal

Advances in protein chemistry and structural biology
ISSN: 1876-1631
Titre abrégé: Adv Protein Chem Struct Biol
Pays: Netherlands
ID NLM: 101497281

Informations de publication

Date de publication:
2024
Historique:
medline: 4 7 2024
pubmed: 4 7 2024
entrez: 3 7 2024
Statut: ppublish

Résumé

We recently identified TMEM230 as a master regulator of the endomembrane system of cells. TMEM230 expression is necessary for promoting motor protein dependent intracellular trafficking of metalloproteins for cellular energy production in mitochondria. TMEM230 is also required for transport and secretion of metalloproteinases for autophagy and phagosome dependent clearance of misfolded proteins, defective RNAs and damaged cells, activities that decline with aging. This suggests that aberrant levels of TMEM230 may contribute to aging and regain of proper levels may have therapeutic applications. The components of the endomembrane system include the Golgi complex, other membrane bound organelles, and secreted vesicles and factors. Secreted cellular components modulate immune response and tissue regeneration in aging. Upregulation of intracellular packaging, trafficking and secretion of endosome components while necessary for tissue homeostasis and normal wound healing, also promote secretion of pro-inflammatory and pro-senescence factors. We recently determined that TMEM230 is co-regulated with trafficked cargo of the endomembrane system, including lysosome factors such as RNASET2. Normal tissue regeneration (in aging), repair (following injury) and aberrant destructive tissue remodeling (in cancer or autoimmunity) likely are regulated by TMEM230 activities of the endomembrane system, mitochondria and autophagosomes. The role of TMEM230 in aging is supported by its ability to regulate the pro-inflammatory secretome and senescence-associated secretory phenotype in tissue cells of patients with advanced age and chronic disease. Identifying secreted factors regulated by TMEM230 in young patients and patients of advanced age will facilitate identification of aging associated targets that aberrantly promote, inhibit or reverse aging. Ex situ culture of patient derived cells for identifying secreted factors in tissue regeneration and aging provides opportunities in developing therapeutic and personalized medicine strategies. Identification and validation of human secreted factors in tissue regeneration requires long-term stabile scaffold culture conditions that are different from those previously reported for cell lines used as cell models for aging. We describe a 3 dimensional (3D) platform utilizing non-biogenic and non-labile poly ε-caprolactone scaffolds that supports maintenance of long-term continuous cultures of human stem cells, in vitro generated 3D organoids and patient derived tissue. Combined with animal component free culture media, non-biogenic scaffolds are suitable for proteomic and glycobiological analyses to identify human factors in aging. Applications of electrospun nanofiber technologies in 3D cell culture allow for ex situ screening and the development of patient personalized therapeutic strategies and predicting their effectiveness in mitigating or promoting aging.

Identifiants

pubmed: 38960479
pii: S1876-1623(24)00034-8
doi: 10.1016/bs.apcsb.2024.03.008
pii:
doi:

Substances chimiques

Membrane Proteins 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

331-360

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Eleonora Piscitelli (E)

Institute of Biomedical Technologies, National Research Council, Milan, Italy.

Iriczalli Cruz Maya (IC)

Institute of Polymers, Composites and Biomaterials, National Research Council, Naples, Italy.

Cinzia Cocola (C)

Institute of Biomedical Technologies, National Research Council, Milan, Italy.

Valentina Martino (V)

Institute of Biomedical Technologies, National Research Council, Milan, Italy.

Edoardo Abeni (E)

Institute of Biomedical Technologies, National Research Council, Milan, Italy.

Paride Pelucchi (P)

Institute of Biomedical Technologies, National Research Council, Milan, Italy.

Elena Angeli (E)

SEELIFE, Department of Physics, University of Genoa, Genoa, Italy.

Patrizia Guida (P)

Department of Physics, University of Genoa, Genoa, Italy.

Arianna Consiglio (A)

Institute of Biomedical Technologies, National Research Council, Bari, Italy.

Giorgio Grillo (G)

Institute of Biomedical Technologies, National Research Council, Bari, Italy.

Theodoros Karnavas (T)

Department of Biology, Touro University New York, New York, NY, United States.

Angelos Gritzapis (A)

Cancer Immunology and Immunotherapy Center, "Agios Savvas" Hospital, Athens, Greece.

Mira Palizban (M)

Department of Gynecology, and Obstetrics, University Hospital of Münster, Münster, Germany.

Ioannis Missitzis (I)

Athens Medical Center, Psychiko Clinic, Athens, Greece.

Martin Götte (M)

Department of Gynecology, and Obstetrics, University Hospital of Münster, Münster, Germany.

Sabino Luini (S)

Institute of Biomedical Technologies, National Research Council, Bari, Italy.

James Kehler (J)

National Institutes of Health, NIDDK, Laboratory of Cell and Molecular Biology, Bethesda, MD, United States.

Cristiana Balbino (C)

I.R.C.C.S. Ospedale Galeazzi-Sant Ambrogio, Department of Orthopedics Rehabilitation, Milan, Italy.

Vincenzo Guarino (V)

Institute of Polymers, Composites and Biomaterials, National Research Council, Naples, Italy. Electronic address: vguarino@unina.it.

Luciano Milanesi (L)

Institute of Biomedical Technologies, National Research Council, Milan, Italy.

Ileana Zucchi (I)

Institute of Biomedical Technologies, National Research Council, Milan, Italy; Associazione Fondazione Renato Dulbecco, Milan, Italy. Electronic address: ileanazucchi@icloud.com.

Alberto Diaspro (A)

SEELIFE, Department of Physics, University of Genoa, Genoa, Italy; Institute of Biophysics, CNR, Genoa, Italy; Nanoscopy, CHT - Istituto Italiano di Tecnologia (IIT), Genoa, Italy.

Rolland Reinbold (R)

Institute of Biomedical Technologies, National Research Council, Milan, Italy; Associazione Fondazione Renato Dulbecco, Milan, Italy. Electronic address: rolland.reinbold@itb.cnr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH